These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9816065)

  • 1. Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer.
    Gabra H; Langdon SP; Watson JE; Hawkins RA; Cohen BB; Taylor L; Mackay J; Steel CM; Leonard RC; Smyth JF
    Clin Cancer Res; 1995 Sep; 1(9):945-53. PubMed ID: 9816065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
    Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
    J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas.
    Leighton X; Srikantan V; Pollard HB; Sukumar S; Srivastava M
    Cancer Lett; 2004 Jul; 210(2):239-44. PubMed ID: 15183540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
    Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
    Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis.
    Gabra H; Watson JE; Taylor KJ; Mackay J; Leonard RC; Steel CM; Porteous DJ; Smyth JF
    Cancer Res; 1996 Mar; 56(5):950-4. PubMed ID: 8640783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of intra-tumoral estradiol level in breast cancer patients.
    Miyoshi Y; Akazawa K; Kamigaki S; Ueda S; Yanagisawa T; Inoue T; Yamamura J; Taguchi T; Tamaki Y; Noguchi S
    Cancer Lett; 2004 Dec; 216(1):115-21. PubMed ID: 15500955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
    Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
    Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus.
    Dodson MK; Cliby WA; Xu HJ; DeLacey KA; Hu SX; Keeney GL; Li J; Podratz KC; Jenkins RB; Benedict WF
    Cancer Res; 1994 Feb; 54(3):610-3. PubMed ID: 8306318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
    Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
    Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
    Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
    Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions.
    Launonen V; Stenbäck F; Puistola U; Bloigu R; Huusko P; Kytölä S; Kauppila A; Winqvist R
    Gynecol Oncol; 1998 Nov; 71(2):299-304. PubMed ID: 9826475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
    Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
    Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
    Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
    Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
    De Sousa Damião R; Fujiyama Oshima CT; Stávale JN; Gonçalves WJ
    Oncol Rep; 2007 Jul; 18(1):25-32. PubMed ID: 17549341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.